---
title: Labial Biopsy in Patients With Tuberculosis Disease
nct_id: NCT02115854
overall_status: COMPLETED
sponsor: Hopital Lariboisière
study_type: OBSERVATIONAL
primary_condition: Tuberculosis
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02115854.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02115854"
ct_last_update_post_date: 2014-04-16
last_seen_at: "2026-05-12T07:06:53.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Labial Biopsy in Patients With Tuberculosis Disease

**Official Title:** The Value of Labial Biopsy in 65 Patients With Tuberculosis Disease

**NCT ID:** [NCT02115854](https://clinicaltrials.gov/study/NCT02115854)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 65
- **Lead Sponsor:** Hopital Lariboisière
- **Conditions:** Tuberculosis, Sarcoidosis
- **Start Date:** 2010-12
- **CT.gov Last Update:** 2014-04-16

## Brief Summary

The distinction between Tuberculosis disease (TB), a worldwide infective granulomatosis requiring long-term antibiotic treatment, and sarcoïdosis, a rare granulomatous disease successfully treated with high dose steroids is not straightforward and may delay the treatment choice by the physician.

The goal was to evaluate prospectively and consecutively the presence of epithelioid granulomas in salivary glands biopsy of patients with TB.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* adults above 18 years,
* bacteriologically confirmed tuberculosis

Exclusion Criteria:

* patient not able to sign written consent
```

## Arms

- **bacteriologically confirmed tuberculosis**

## Interventions

- **labial biopsy** (OTHER)

## Primary Outcomes

- **presence of granuloma on labial biopsy** _(time frame: at day zero of treatment of tuberculosis)_

## Locations (1)

- Unite de Recherche Thérapeutique, Paris, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.unite de recherche thérapeutique|paris||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02115854.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02115854*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*